Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease
المؤلفون المشاركون
Seiple, W. H.
Gordon, Mark Forrest
Jennings, Danna
Borchert, Leona
Canale, Lee
Fagan, Nora
Rosen, Richard
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-12-18
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
Background.
Parkinson’s disease (PD) progressively affects dopaminergic neurotransmission and may affect retinal dopaminergic functions and structures.
Objective.
This 2-year randomized, open-label, parallel-group, flexible-dose study, NCT00144300, evaluated ophthalmologic safety profiles of immediate-release (IR) pramipexole and ropinirole in patients with early idiopathic PD with ≤6 months’ prior dopamine agonist exposure and without preexisting major eye disorders.
Methods.
Patients received labeled IR regimens of pramipexole (n=121) or ropinirole (n=125) for 2 years.
Comprehensive ophthalmologic assessments (COA) included corrected acuity, Roth 28-color test, slit-lamp biomicroscopy, intraocular pressure, computerized visual field test, fundus photography, and electroretinography.
Results.
At baseline, we observed retinal pigmentary epithelium (RPE) hypopigmentation not previously reported in PD patients.
The estimated relative risk of 2-year COA worsening with pramipexole versus ropinirole was 1.07 (95% CI: 0.71–1.60).
Mean changes from baseline in Unified Parkinson’s Disease Rating System parts II+III total scores (pramipexole: 1 year, −4.1±8.9, and 2 years, −0.7±10.1, and ropinirole: 1 year, −3.7±8.2, and 2 years, −1.7±10.5) and Hoehn–Yahr stage distribution showed therapeutic effects on PD symptoms.
Safety profiles were consistent with labeling.
Conclusions.
The risk of retinal deterioration did not differ in early idiopathic PD patients receiving pramipexole versus ropinirole.
RPE hypopigmentation at baseline was not previously reported in this population.
This trial is registered with NCT00144300.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Seiple, W. H.& Jennings, Danna& Rosen, Richard& Borchert, Leona& Canale, Lee& Fagan, Nora…[et al.]. 2016. Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease. Parkinson’s Disease،Vol. 2016, no. 2016, pp.1-14.
https://search.emarefa.net/detail/BIM-1115269
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Seiple, W. H.…[et al.]. Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease. Parkinson’s Disease No. 2016 (2016), pp.1-14.
https://search.emarefa.net/detail/BIM-1115269
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Seiple, W. H.& Jennings, Danna& Rosen, Richard& Borchert, Leona& Canale, Lee& Fagan, Nora…[et al.]. Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease. Parkinson’s Disease. 2016. Vol. 2016, no. 2016, pp.1-14.
https://search.emarefa.net/detail/BIM-1115269
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1115269
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر